Last reviewed · How we verify
NCT06688539: VapeCAT
E-cigarette Cessation in Adults Who Co-use Cannabis
Phase 4 trial testing Varenicline Pill in Nicotine Dependence in 105 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Medical University of South Carolina |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 105 |
| Start date | 19 February 2025 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 September 2026 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Varenicline Pill — full drug profile →
- Contingency management
- Counseling
Conditions studied
- Nicotine Dependence — all drugs for Nicotine Dependence →
- Tobacco Use Disorder — all drugs for Tobacco Use Disorder →
Sponsor
Medical University of South Carolina
Who can join
Adults 18 to 40, any sex, with Nicotine Dependence or Tobacco Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06688539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Varenicline Pill
Trials testing the same drug.
- NCT04188106 — Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment · Phase 4 · completed
- NCT03553173 — So-Lo-Mo Intervention Applied to the Smoking Cessation Process · NA · completed
- NCT01511614 — Nicotine Withdrawal Symptoms and Smoking Relapse · NA · completed
Other recruiting trials for Nicotine Dependence
Currently open trials in the same condition.
- NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
- NCT07250230 — Effect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Un · NA · recruiting
- NCT07040566 — A Trial of Varenicline for E-cigarette Cessation · Phase 2 · recruiting
- NCT07001930 — Effects of Cannabidiol on Stress and Nicotine Withdrawal · Phase 1 · recruiting
- NCT06765291 — Behavioral Intervention for Youth to Promote Vaping Cessation · NA · recruiting
Other Medical University of South Carolina trials
Trials by the same sponsor.
- NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
- NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
- NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
- NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06688539 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
- Last refreshed: 7 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06688539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing